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Abstract
Objective Our objective was to assess healthcare resource utilization (HRU) and costs among patients with major depressive
disorder (MDD) with and without treatment-resistant depression (TRD) and those without MDD in US Integrated Delivery
Networks (IDNs).
Methods This was a retrospective matched-cohort study. The Optum© Integrated Claims Electronic Health Record deidentified database was used to identify adult patients with TRD (January 2011–June 2017) across US IDNs. TRD patients
were propensity score matched 1:1 with non-TRD MDD and non-MDD patients on demographics. Rates of HRU and costs
were compared up to 2 years following the first antidepressant pharmacy claim (or randomly imputed date for non-MDD
patients) using negative binomial and ordinary least squares regressions, respectively, with 95% confidence intervals (CIs)
from nonparametric bootstraps (costs only) adjusted for baseline comorbidity index and costs.
Results All 1582 TRD patients were matched to non-TRD MDD and non-MDD patients and evaluated. TRD patients were
on average 46 years old, and 67% were female. Mean duration of observation was 20.1, 19.6, and 17.9 months in the TRD,
non-TRD MDD, and non-MDD cohorts, respectively. Patients with TRD had significantly higher rates of HRU than did
non-TRD MDD patients (inpatient visits 0.35 vs. 0.16 per patient per year [PPPY]; adjusted incidence rate ratio [IRR] 2.04
[95% CI 1.74–2.39]) and non-MDD patients (0.35 vs. 0.09 PPPY, adjusted IRR 3.05 [95% CI 2.54–3.66]). TRD patients
incurred significantly higher costs PPPY than did non-TRD MDD patients ($US25,807 vs. 13,701, adjusted cost difference
$US9479 [95% CI 7071–11,621]) and non-MDD patients ($US25,807 vs. 8500, adjusted cost difference $US11,433 [95%
CI 8668–13,876]).
Conclusions HRU and costs associated with TRD are significant in US IDNs.

1 Introduction
Major depressive disorder (MDD) is a debilitating psychiatric disorder characterized by a loss of interest in previously enjoyable activities, chronic depression, and suicidal
ideations [1]. MDD is one of the most prevalent behavioral
health disorders in the United States (US) [2, 3], representing 6.7% (16.2 million adults) of the overall population [2].
The economic burden associated with MDD was estimated
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at $US210.5 billion in 2010, with 45–47% of this burden
attributed to direct healthcare costs and 48–50% due to
workplace costs [4].
Antidepressant therapy represents the standard of care
for patients with MDD; however, a considerable portion of
patients (approximately 30%) develop treatment-resistant
depression (TRD) [5], which is commonly defined as the
failure to respond to at least two different antidepressants
that are of adequate dose and duration [6, 7]. Although the
health and economic burdens associated with MDD are
considerable, recent studies have shown that patients with
TRD experience an economic burden that is typically twoto-threefold higher than patients who respond to treatment
[8, 9]. A recent study examining direct healthcare costs associated with TRD found that TRD patients had greater healthcare resource utilization (HRU) that resulted in considerably
higher direct costs per patient per year (TRD $US17,261;
non-TRD MDD $US9790; non-MDD $US4781) [8].
Modification of therapeutic approaches with each failed
response requires TRD patients to seek ongoing care from
healthcare providers across multiple settings [6, 10, 11].
However, fragmented care resulting from the lack of coordination among different healthcare providers and organizations can interfere with the continuity of measurement-based
care required to treat these patients [12, 13]. To overcome
this challenge, collaborative care models such as integrated
delivery networks (IDNs) have been proposed [11, 14].
Despite variations in the structure of IDNs, they are broadly
defined as healthcare organizations that consist of multiple physicians, hospitals, and other sources of patient care
[15–18]. IDNs are increasingly recognized for their capacity
to provide quality care across a continuum of settings (e.g.,
hospitals, health clinics, community health centers) within
a single system [11, 19–21].
As organizations dedicated to coordinated patient care,
IDNs typically assume financial accountability for patient
outcomes, which is often associated with increased efficiency and reduced healthcare costs [11]. Although care in
IDNs is expected to decrease costs, conclusive evidence is
lacking [15]. IDNs are commonly discussed within the context of improved quality of care [22], yet evidence regarding the costs among MDD and TRD patients treated within
US IDNs is sparse. The limited number of reports assessing behavioral health services in collaborative care models
[15, 23, 24] have focused on heterogeneous populations of
depressed patients who often have other comorbidities. As a
result, these reports may not accurately capture the costs of
care among TRD and non-TRD MDD patients. Therefore,
this study was conducted to describe the HRU and costs
among three cohorts of patients—those with TRD, those
with non-TRD MDD, and those with no evidence of MDD—
who were treated within IDNs in the US.
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2 Methods
2.1 Data Source
Optum Integrated Claims Electronic Health Records
(EHRs) from 1 January 2011 to 30 June 2017 was used
for this study. This database included information on > 10
million individuals insured by UnitedHealth Group with
their adjudicated claims linked to Humedica’s EHR. Data
were de-identified and compliant with the requirements
outlined in the Health Insurance Portability and Accountability Act.

2.2 Study Design
This retrospective matched-cohort study comprised three
mutually exclusive TRD, non-TRD MDD, and non-MDD
cohorts. The first antidepressant pharmacy claim (on or
after 1 July 2011 for TRD and non-TRD MDD patients,
and randomly imputed dates on or after 1 July 2011 for
non-MDD patients) was defined as the index date. Patient
characteristics were evaluated in the 6 months that preceded the index date (baseline period), and study outcomes (treatment patterns, HRU, and costs) were evaluated from the index date up to 2 years post-index date,
the end of continuous enrollment in a health insurance
plan, or end of data availability (30 June 2017), whichever
occurred first. Since the average time to become TRD was
reported to be 1.3 years [6], a 2-year period was used to
allow MDD patients the opportunity to be classified as
TRD.
Patients with one or more visits to an IDN were considered IDN patients. Once patients were seen in an IDN,
they remain flagged as IDN patients even if they later
received care in a non-IDN setting. The IDN indicator was
not determined at the patient level and was therefore not
time or visit specific. Although a consensus definition of an
IDN is lacking [15], an IDN was defined as a coordinated
hospital inpatient and outpatient system that offers healthcare services in a defined geographic area in the Optum
database. Multiple coordinated hospitals or IDNs could be
included. IDNs that were included are primarily hospital
based in Optum, but they provide more comprehensive services than solely inpatient care. Moreover, Optum defined
an IDN as a provider network-level variable; providers
self-identified whether they were IDNs and were required
to have inpatient data to support their status as IDNs. In
this study, 80.1% of the MDD cohort were associated with
an IDN, whereas 75.7% were associated in the non-MDD
cohort (Tables S1–2).
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2.3 Study Cohorts

2.3.3 Non‑MDD Cohort

Patients with TRD (TRD cohort) were compared with
two control cohorts: patients with MDD who did not have
TRD (non-TRD MDD cohort) and patients without MDD
(non-MDD cohort). Patients in both control cohorts were
propensity score (PS) matched 1:1 with patients in the
TRD cohort.
To be included in both the TRD and the non-TRD MDD
cohorts, patients were required to meet the following criteria: (1) one or more diagnoses for MDD (International
Classification of Diseases, Ninth Edition, Clinical Modification [ICD-9-CM]: 296.2x [MDD – single episode], 296.3x
[MDD – recurrent episode]; ICD, Tenth Edition, CM [ICD10-CM]: F32.x [excluding F32.8], F33.x [excluding F33.8]);
(2) one or more claims for an antidepressant between 1 July
2011 and 30 June 2017 (MDD diagnosis could occur before
or after the first antidepressant pharmacy claim); (3) one or
more diagnoses of depression (ICD-9-CM: 296.2x, 296.3x,
300.4x, 311.x, 309.0x, or 309.1x; ICD-10-CM: F32.x,
F33.x, F34.1, or F43.21) during the baseline or observation
period. Both the baseline and follow-up periods were used to
identify patients with depression due to the episodic nature
of the disease [25].

Patients in the non-MDD cohort consisted of a randomly
selected sample of patients without MDD (ICD-9-CM:
296.2x, 296.3x; ICD-10-CM: F32.x, F33.x [excluding
F33.8]) from 1 January 2011 to 30 June 2017. Since a retrospective matched-cohort study design was used, the random
selection of 500,000 non-MDD patients was considered sufficient to provide a pool of controls eligible for matching.

2.3.1 Treatment‑Resistant Depression (TRD) Cohort
In the TRD cohort, a pharmacy claims-based algorithm was
used to identify MDD patients who were likely to have TRD
within 2 years after the index date (i.e., follow-up). MDD
patients were considered likely to have TRD if their MDD
did not respond to two antidepressant treatment regimens,
including augmentation therapy with an anticonvulsant,
anxiolytic, antipsychotic, lithium, psychostimulant, or thyroid hormone medication, with adequate dose and duration
(> 6 weeks) as per the American Psychiatric Association
guidelines [7]. Failure of a treatment regimen was defined
as a switch of antidepressant (i.e., < 180 days after the end
of the previous treatment), the addition of an antidepressant,
or the initiation of an augmentation therapy. The initiation
of the third treatment regimen had to occur > 6 weeks after
the start of the first antidepressant treatment.
2.3.2 Non‑TRD Major Depressive Disorder (MDD) Cohort
Patients in the non-TRD MDD cohort included MDD
patients who did not meet the criteria for TRD, as previously defined, within 2 years of the index date.

2.3.4 All Cohorts
All patients included in this study were required to meet
the following conditions: (1) no diagnosis for specific psychiatric comorbidities (i.e., psychosis [ICD-9-CM: 298.xx;
ICD-10-CM: F23.x, F25.x, F44.89], schizophrenia [ICD9-CM: 295.xx; ICD-10-CM: F20.x, F25.x], bipolar disorder/manic depression [ICD-9-CM: 296.0x, 296.1x, 296.4x,
296.5x, 296.6x, 296.7x, 296.8x; ICD-10-CM: F30.x, F31.x],
dementia [ICD-9-CM: 290.xx, 294.1x; ICD-10-CM: F01.x,
F02.x, F03.x]) between 1 January 2011 and 30 June 2017;
(2) ≥ 18 years at the index date; (3) ≥ 6 months of continuous
enrollment in a health insurance plan before and after the
index date; (4) no antidepressant claims during the baseline
period.

2.4 Study Measures
Baseline characteristics included demographics, physical
and mental comorbidities, medication use, HRU, and costs
were used to assess the distribution of the TRD, non-TRD,
and non-MDD cohorts.
For each cohort, the proportion of patients receiving antidepressant medications during the observation period was
reported. Duration of antidepressant therapy was also presented and defined as the number of days with medication
available between the first antidepressant claim (i.e., index
date) and the last day of supply of antidepressant with no
gaps > 14 days (gaps were excluded in duration of therapy).
HRU and costs were categorized as all-cause, behavioral
health-related, depression-related, and suicide-related. For
each category, HRU and costs were divided into inpatient
visits, inpatient days, emergency department (ED) visits,
outpatient visits, and other visits. Behavioral health-related
medical HRU and costs (including depression-related but
not suicide-related costs) were identified using primary
or secondary ICD-9-CM diagnostic codes 290.xx–319.
xx and ICD-10-CM diagnostic codes F01.xxx–F99.xxx.
Psychiatric pharmacy costs included the following classes
of agents: anxiolytics, antidepressants, anticonvulsants/
mood stabilizers, antipsychotics, and other mood stabilizers (e.g., lithium). Depression-related HRU and costs were
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identified using primary or secondary ICD-9-CM diagnostic codes 296.2x, 296.3x, 300.4x, 309.0x, 309.1x, 311.xx
and ICD-10-CM diagnostic codes F32.x, F33.x, F34.1, or
F43.21. Antidepressant pharmacy costs included the following classes of agents, selective serotonin reuptake inhibitors (SSRIs), norepinephrine-dopamine reuptake inhibitors
(NDRIs), serotonin-norepinephrine reuptake inhibitors
(SNRIs), serotonin modulators (i.e., nefazodone, trazodone, vilazodone, venlafaxine), tricyclics and tetracyclics,
norepinephrine-serotonin modulators, monoamine oxidase
inhibitors (MAOIs), and other (i.e., olanzapine-fluoxetine).
Suicide-related HRU and costs were defined using primary
or secondary ICD-9-CM diagnostic codes E95x or V62.84
and ICD-10-CM diagnostic codes T14.91x, X71.x-X83.x,
T36.x- T65.x with a suffix of ‘2’ indicating ‘intentional selfharm’, T71.x with a suffix of ‘2’ indicating ‘intentional selfharm’ or R45.851.

2.5 Statistical Analysis
Patients with TRD were matched 1:1 to non-TRD MDD
and non-MDD patients using PS defined as the conditional
probability of having TRD based on observable characteristics [26, 27]. The PS across patients were classified into
strata, each containing an equal proportion of patients (5%).
One TRD patient was matched to one non-TRD MDD and
one non-MDD patient within the same stratum. The logistic
regression model was used to estimate the PS, where having TRD (yes/no) was the binary dependent variable and
patient characteristics were the predictors and included age,
sex, race, year of the index date, geographical region, and
type of healthcare plan. Baseline patient characteristics were
compared using standardized differences; a covariate with
a standardized difference < 10% was considered well-balanced [26]. Rates of HRU were compared between matched
cohorts using multivariable negative binomial regression
(i.e., incidence rate ratios [IRRs]). Costs were expressed as
per patient per year (PPPY) in $US, year 2017 values, using
the Consumer Price Index for Medical care using means,
standard deviations (SDs), and medians, and adjusted cost
differences were calculated using multivariable ordinary
least squares regression with 95% confidence intervals (CIs)
and p-values obtained from nonparametric bootstraps with
499 replications. To account for censoring in the cost data,
a phase-based approach has been recommended in studying
cumulative costs [28]. Specifically, mean costs per patient
per month (PPPM) in the 6 months before and up to 2 years
after the index date and stratified by 1-month periods were
calculated as a sensitivity analysis. Since the matching was
limited to demographic variables, baseline Quan-Charlson
comorbidity index (Quan-CCI) [29] and all-cause healthcare costs were adjusted for in the multivariable models
due to the remaining imbalances observed after matching.
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Given that TRD is complex, with multifactorial causes and
effects with respect to other comorbidities, minimally matching on and controlling for potential confounders to avoid
conditioning on mediators was deemed appropriate in this
context. For the parameter estimates, standard errors, and
Akaike information criterion from the regression models,
see Tables S3–7.

3 Results
3.1 Baseline Demographic and Clinical
Characteristics
Among 12,730 treated patients with MDD, 1582 (12%) met
the criteria for TRD (Table S1). A total of 63,828 patients
without MDD who met the inclusion criteria were identified
(Table S2). Before matching, TRD patients were younger
than non-TRD MDD and non-MDD patients (Table S8).
After matching, cohorts were well-balanced (standardized
difference < 10%) on demographic factors (Table 1). TRD
patients were more likely to have other behavioral healthrelated medication use during the baseline period, even
after matching. See Figs. S1–S2 for PS distributions. The
mean duration of the observation period was 20.1, 19.6, and
17.9 months in the TRD, non-TRD MDD, and non-MDD
cohorts, respectively.

3.2 Treatment Patterns
Patients with TRD used a greater variety of antidepressants than did patients in the other cohorts. In the TRD and
non-TRD MDD cohorts, the three most frequently used
antidepressants included SSRIs (89 vs. 81%), NDRIs (47
vs. 22%), and SNRIs (45 vs. 16%; Fig. 1). The use of antidepressants was low in the non-MDD cohort (SSRIs 8%,
NDRIs 2%, and SNRIs 2%). The duration of antidepressant
therapy was longer among TRD patients than among nonTRD MDD and non-MDD patients (Table S9).

3.3 Healthcare Resource Utilization (HRU) and Costs
Patients with TRD had higher rates of HRU during the
observation period than did the non-TRD MDD and nonMDD patients (Fig. 2). TRD patients had 2.04 (95% CI
1.74–2.39) and 3.05 (95% CI 2.54–3.66) times the rate of
inpatient visits for non-TRD MDD and non-MDD patients,
respectively. All-cause inpatient length of stay was higher
for TRD patients (3.19 days) than for non-TRD (1.04 days)
and non-MDD (0.78 days) patients (adjusted IRR 2.98
[95% CI 2.34–3.81] and 2.43 [95% CI 1.85–3.20], respectively). Similarly, TRD patients had higher rates of behavioral health-related HRU (e.g., 2.61 [95% CI 2.23–3.06]
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Table 1  Baseline characteristics, healthcare resource utilization, and all-cause healthcare costs evaluated 6 months prior to the index date
Variables

Matched populationa
TRD cohort

Non-TRD MDD cohort Std. diff.b (%) Non-MDD control cohort Std. diff.b (%)

N = 1582

N = 1582

Age at index date, years
45.6 ± 16.6 [45]
Female
1052 (66.5)
Race
White
1345 (85.0)
Black
68 (4.3)
Asian
16 (1.0)
Hispanic
51 (3.2)
Other/unknown
102 (6.4)
c
Year of index d ate
2011
215 (13.6)
2012
266 (16.8)
2013
260 (16.4)
2014
250 (15.8)
2015
292 (18.5)
2016
246 (15.5)
2017
53 (3.4)
d
Geographical region
Northeast
160 (10.1)
Midwest
792 (50.1)
South
396 (25.0)
West
191 (12.1)
Unknown
43 (2.7)
Type of healthcare plan
Medicare
283 (17.9)
Commercial
1299 (82.1)
Preferred provider organization
78 (4.9)
Point of service plan
907 (57.3)
Health management organization 189 (11.9)
Exclusive provider organization
84 (5.3)
Other healthcare plan
41 (2.6)
Quan-CCI [29]
0.6 ± 1.3 [0]
Number of unique mental health
1.2 ± 1.6 [1]
diagnoses
Other mental health-related medi- 614 (38.8)
cation use [42, 43]e
Top five most frequent physical comorbidities [44]f
Hypertension
405 (25.6)
Diabetes
196 (12.4)
Chronic pulmonary disease
167 (10.6)
Obesity
127 (8.0)
Hypothyroidism
140 (8.8)
Top five most frequent mental c omorbiditiesg
Depressionh
556 (35.1)
Anxiety disorders
345 (21.8)
Sleep–wake disorders
220 (13.9)
Substance-related and addictive
188 (11.9)
disorders

N = 1582

45.4 ± 16.7 [44]
1067 (67.4)

0.7
2.0

44.9 ± 16.8 [44]
1088 (68.8)

4.1
5.0

1339 (84.6)
69 (4.4)
15 (0.9)
68 (4.3)
91 (5.8)

1.1
0.3
0.6
5.7
2.9

1313 (83.0)
58 (3.7)
15 (0.9)
76 (4.8)
120 (7.6)

5.4
3.2
0.6
8.1
4.5

203 (12.8)
256 (16.2)
262 (16.6)
243 (15.4)
294 (18.6)
274 (17.3)
50 (3.2)

2.2
1.7
0.3
1.2
0.3
4.8
1.1

224 (14.2)
273 (17.3)
286 (18.1)
259 (16.4)
291 (18.4)
249 (15.7)
0 (0.0)

1.6
1.2
4.4
1.6
0.2
0.5
25.9

163 (10.3)
768 (48.5)
419 (26.5)
178 (11.3)
54 (3.4)

0.6
3.0
3.3
2.6
4.0

163 (10.3)
807 (51.0)
378 (23.9)
185 (11.7)
49 (3.1)

0.6
1.9
2.6
1.2
2.3

259 (16.4)
1323 (83.6)
85 (5.4)
908 (57.4)
187 (11.8)
93 (5.9)
50 (3.2)
0.5 ± 1.1 [0]
0.9 ± 1.3 [0]

4.0
4.1
2.0
0.1
0.4
2.5
3.4
12.1
20.8

254 (16.1)
1328 (83.9)
84 (5.3)
955 (60.4)
176 (11.1)
71 (4.5)
42 (2.7)
0.3 ± 0.9 [0]
0.2 ± 0.5 [1]

4.9
5.0
1.7
6.3
2.6
3.8
0.4
29.0
84.3

343 (21.7)

35.2

152 (9.6)

62.4

338 (21.4)
147 (9.3)
157 (9.9)
128 (8.1)
121 (7.6)

9.9
9.9
2.1
0.2
4.4

243 (15.4)
92 (5.8)
94 (5.9)
78 (4.9)
100 (6.3)

24.6
22.5
16.6
12.5
9.5

478 (30.2)
245 (15.5)
154 (9.7)
116 (7.3)

10.3
15.9
12.8
15.3

37 (2.3)
70 (4.4)
65 (4.1)
55 (3.5)

76.7
49.1
33.3
30.9
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Table 1  (continued)
Variables

Other conditions that may be a
focus of clinical attention
Had ≥ 1 healthcare visit/service
Inpatient
ED
Outpatient
Other
All-cause healthcare costs ($US,
year 2017 values)
Medical costs
Pharmacy costs

Matched populationa
TRD cohort

Non-TRD MDD cohort Std. diff.b (%) Non-MDD control cohort Std. diff.b (%)

N = 1582

N = 1582

121 (7.6)

110 (7.0)

2.7

65 (4.1)

14.9

217 (13.7)
203 (12.8)
1398 (88.4)
366 (23.1)
21,872 ± 61,869 [4937]

144 (9.1)
178 (11.3)
1342 (84.8)
306 (19.3)
13,696 ± 44,271 [2643]

14.3
4.8
9.8
9.2
15.2

57 (3.6)
112 (7.1)
1180 (74.6)
193 (12.2)
7160 ± 24,755 [1350]

35.0
18.9
30.3
27.8
31.2

5918 ± 23,754 [868]
1242 ± 5943 [105]

30.2
13.1

N = 1582

19,802 ± 60,601 [3363] 12,357 ± 43,421 [1740] 14.1
2070 ± 6719 [420]
1339 ± 4201 [230]
13.0

Data are presented as n (%) or mean ± standard deviation [median] unless otherwise indicated
ED emergency department, ICD-x-CM International Classification of Diseases, xth edition, Clinical Modification, MDD major depressive disorder, Quan-CCI Quan-Charlson comorbidity index, SD standard deviation, Std. diff. standardized difference, TRD treatment-resistant depression
a

Patients were matched on propensity score (the probability of being in the TRD cohort vs. the non-TRD MDD or non-MDD cohort), modelled
using a logistic regression model adjusted for categorical age, sex, race, year of the index date, geographical region, and type of healthcare plan

b
For continuous variables, the std. diff. was calculated by dividing the absolute difference in means of the control and the TRD cohorts by the
pooled SD of both groups. The pooled SD is the square root of the average of the squared SDs. For dichotomous variables, the std. diff. was calculated using the following equation, where P is the respective proportion of participants in each group: (PTRD − Pcontrol)/√[(PTRD(1 − PTR
D) + Pcontrol(1 − Pcontrol))/2]
c

For TRD and non-TRD MDD patients, the index date was defined as the date of the first prescription fill for an antidepressant. For non-MDD
patients, the index date was randomly generated

d
e

Based on US census regions (http://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf)

Includes anxiolytics, anticonvulsants/mood stabilizers, antipsychotics, psychostimulants, thyroid hormone (T3), and lithium. Agents were
grouped according to their generic name

f

The top five most frequent Elixhauser comorbidities identified in the TRD cohort were reported

g
h

The top five most frequent mental disorders identified in the TRD cohort were reported

Depression diagnoses included the following diagnoses ICD-9-CM: 296.2x (MDD—single episode), 296.3x (MDD—recurrent episode),
300.4x (dysthymic disorder), 309.0x (adjustment disorder with depressed mood), 309.1x (prolonged depressive reaction), and 311.x (depressive
disorder, not elsewhere classified) or ICD-10-CM: F32x (MDD—single episode), F33x (MDD—recurrent episode), F341 (dysthymic disorder)
and F4321 (adjustment disorder with depressed mood). All patients had to have a diagnosis of MDD during the study period, but only a portion
had an MDD diagnosis during the baseline period

and 17.44 [95% CI 11.62–26.16] times the rate of inpatient
visits for TRD patients vs. non-TRD MDD and non-MDD
patients, respectively); the rate of depression- and suiciderelated inpatient visits was 2.48 (95% CI 1.98–3.11) and
3.26 (95% CI 2.28–4.68), respectively, times higher for the
TRD than for the non-TRD MDD patients (Table S10).
During the baseline period, the mean all-cause healthcare
cost PPPY was $US21,872, $US13,696, and $US7160 for
TRD, non-TRD MDD, and non-MDD patients, respectively
(Table 1). For the TRD and non-TRD MDD cohorts, allcause medical costs were $US19,802 and 12,357, respectively, which accounted for > 90% of all-cause healthcare
costs. During the follow-up period, the unadjusted cost
differences PPPY illustrated that all-cause healthcare costs

for the TRD cohort were 88% and 304% higher than for
the non-TRD MDD and non-MDD cohorts ($US25,807
[TRD] vs. 13,701 [non-TRD MDD] or 8500 [non-MDD];
Table 2). After adjusting for baseline Quan-CCI and allcause healthcare costs, TRD patients had significantly higher
PPPY all-cause healthcare costs than did non-TRD MDD
and non-MDD patients ($US9479 [95% CI 7071–11,621]
more than the non-TRD MDD cohort and $US11,433 [95%
CI 8668–13,876] more than the non-MDD cohort; Fig. 3).
Similarly, TRD patients had the highest all-cause inpatient
costs ($US3805 [95% CI 2289–5268] more than the nonTRD MDD cohort and $US4199 [95% CI 2566–5484] more
than the non-MDD cohort), which were the main drivers of
the adjusted cost difference (Table 2). Additionally, mean

125

Economic Burden of TRD in US IDNs

Fig. 1  Medication treatment patterns during the observation period
among TRD, non-TRD MDD, and non-MDD cohorts. MDD major
depressive disorder, NDRIs norepinephrine-dopamine reuptake

(a)

inhibitors, SNRIs serotonin-norepinephrine reuptake inhibitors, SSRIs
selective serotonin reuptake inhibitors, TRD treatment-resistant
depression

D cohort versus non-TRD MDD cohort

Healthcare resource
utilization, PPPY

TRD

Non-TRD
MDD

Adjusted IRR
(95% CI)

P-value

0.35

0.16

2.04 (1.74 - 2.39)

<0.001*

3.19

1.04

2.98 (2.34 - 3.81)

<0.001*

ED visits

0.84

0.59

1.40 (1.14 - 1.71)

0.001*

Outpatient visits

21.97

14.08

1.50 (1.42 - 1.59)

<0.001*

Other visits

2.73

1.87

1.27 (1.08 - 1.49)

0.004*

Inpatient visits
Number of days

0.0

(b)

D cohort versus non-MDD cohort

1.0

2.0

3.0

4.0

Higher rate among TRD cohort versus control cohort

Healthcare resource
utilization, PPPY

TRD

Non-MDD

Adjusted IRR
(95% CI)

P-value

Inpatient visits

0.35

0.09

3.05 (2.54 - 3.66)

<0.001*

3.19

0.78

2.43 (1.85 - 3.20)

<0.001*

ED visits

0.84

0.42

1.86 (1.50 - 2.31)

<0.001*

Outpatient visits

21.97

8.16

2.66 (2.49 - 2.84)

<0.001*

Other visits

2.73

0.91

2.29 (1.93 - 2.73)

<0.001*

Number of days

0.0

1.0

2.0

3.0

4.0

30

Higher rate among TRD cohort versus control cohort

Fig. 2  Healthcare resource utilization measured from the index date
up to 2 years post-index 
datea. aMultivariable negative binomial
regression included baseline all-cause healthcare costs and QuanCCI. *Significant at the 5% level. CI confidence interval, ED emer-

gency department, HRU healthcare resource utilization, IRR incidence rate ratio, MDD major depressive disorder, PPPY per patient
per year, Quan-CCI Quan–Charlson comorbidity index, TRD treatment-resistant depression

1180 ± 2630 [345]
214 ± 1553 [0]
30 ± 286 [0]
899 ± 1913 [289]
37 ± 387 [0]
316 ± 701 [109]
830 ± 1556 [335]
593 ± 1482 [156]
119 ± 996 [0]
14 ± 139 [0]
439 ± 1058 [135]
20 ± 158 [0]
237 ± 477 [84]
52 ± 617 [0]
44 ± 608 [0]
1 ± 14 [0]
8 ± 109 [0]
0 ± 0 [0]

2675 ± 5927 [956]
657 ± 3985 [0]
74 ± 511 [0]
1841 ± 3463 [779]
104 ± 1178 [0]
998 ± 1501 [450]
1810 ± 3246 [825]
1270 ± 3162 [341]
380 ± 2072 [0]
27 ± 350 [0]
816 ± 2084 [274]
47 ± 619 [0]
540 ± 781 [259]
177 ± 1541 [0]
156 ± 1525 [0]
1 ± 21 [0]
17 ± 149 [0]
2 ± 68 [0]

43 ± 625 [0]
13 ± 504 [0]
5 ± 132 [0]
22 ± 283 [0]
4 ± 127 [0]
28 ± 309 [0]
2 ± 66 [0]
0 ± 0 [0]
0 ± 2 [0]
2 ± 66 [0]
0 ± 2 [0]

57 ± 833 [0]
16 ± 234 [0]
118 ± 666 [0]
10 ± 193 [0]
42 ± 333 [0]
72 ± 708 [0]

200 ± 1163 [0]

1582
8500 ± 28,085 [2189]
7249 ± 26,921 [1574]
2102 ± 15,222 [0]
267 ± 1483 [0]
4382 ± 17,958 [1156]
498 ± 4214 [0]
1251 ± 5094 [150]
242 ± 1225 [0]

Non-MDD cohort [C]

672 (489–863); < 0.001*
261 (152–384); < 0.001*
12 (− 4 to 34); 0.172
376 (270–502); < 0.001*
23 (− 4 to 54); 0.092
300 (260–347); < 0.001*
128 (53–210); < 0.001*
116 (40–195); < 0.001*
0 (− 1 to 2); 0.481
10 (1–20); 0.024*
2 (0–4); < 0.001*

433 (253–674); < 0.001*
40 (8–71); 0.004*
928 (737–1112); < 0.001*
59 (11–116); 0.024*
677 (598–765); < 0.001*
973 (785–1162); < 0.001*

1460 (1160–1781); < 0.001*

9479 (7071–11,621); < 0.001*
7818 (5422–9855); < 0.001*
3805 (2289–5268); < 0.001*
528 (263–839); < 0.001*
3011 (1751–4013); < 0.001*
474 (− 43 to 925); 0.072
1661 (1278–2073); < 0.001*
2137 (1805–2485); < 0.001*

[A vs. B]

1218 (1064–1389); < 0.001*
367 (272–484); < 0.001*
22 (5–44); 0.004*
794 (688–908); < 0.001*
35 (13–63); < 0.001*
507 (463–553); < 0.001*
182 (112–258); < 0.001*
164 (94–241); < 0.001*
1 (0–2); 0.004*
16 (9–26); < 0.001*
1 (− 1 to 2); 0.313

578 (398–797); < 0.001*
49 (24–78); < 0.001*
1702 (1530–1883); < 0.001*
77 (32–130); < 0.001*
948 (876–1032); < 0.001*
1725 (1566–1898); < 0.001*

2406 (2135–2732); < 0.001*

11,433 (8668–13,876); < 0.001*
9468 (6785–11,722); < 0.001*
4199 (2566–5484); < 0.001*
493 (221–770); < 0.001*
4075 (2252–5598); < 0.001*
701 (59–1256); 0.024*
1964 (1544–2406); < 0.001*
3355 (3072–3699); < 0.001*

[A vs. C]

Behavioral health-related costs were defined as all costs during a visit with any of the following ICD-9-CM diagnostic codes: 290.xx-319.xx and ICD-10-CM diagnostic codes: F01.xxx-F99.
xxx

a

CI confidence interval, ED emergency department, ICD-x-CM International Classification of Diseases, xth revision, Clinical Modification, MDD major depressive disorder, PPPY per patient per
year, Quan-CCI Quan-Charlson comorbidity index, TRD treatment-resistant depression

Data are presented as mean ± standard deviation [median] or as adjusted cost difference (95% CI); multivariable ordinary least squares regression included baseline all-cause healthcare costs
and Quan-CCI. Costs are presented as $US, year 2017 values

1582
13,701 ± 27,545 [5394]
11,752 ± 26,061 [4027]
3304 ± 14,630 [0]
409 ± 1744 [0]
7025 ± 15,417 [3007]
1014 ± 7966 [0]
1949 ± 4433 [650]
1496 ± 2742 [627]

1582
25,807 ± 42,549 [11,931]
21,908 ± 39,844 [8896]
7897 ± 25,551 [0]
1090 ± 5742 [0]
11,277 ± 21,406 [5352]
1644 ± 6462 [0]
3899 ± 8024 [1754]
3673 ± 6246 [1855]

Overall population
All-cause medical and pharmacy costs
All-cause medical costs
Inpatient costs
ED costs
Outpatient costs
Other costs
All-cause pharmacy costs
Behavioral health-related medical and
pharmacy costs
Behavioral health-related medical
costsa
Inpatient costs
ED costs
Outpatient costs
Other costs
Psychiatric pharmacy costsb
Depression-related medical and pharmacy costs
Depression-related medical c ostsc
Inpatient visits
ED visits
Outpatient costs
Other costs
Antidepressant pharmacy costs
Suicide-related medical costsd
Inpatient visits
ED visits
Outpatient costs
Other costs

Non-TRD MDD cohort [B]

TRD cohort [A]

Healthcare cost PPPY

Table 2  Healthcare costs per patient per year by type of visit, measured from the index date up to 2 years post-index date
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costs PPPM in the 6 months before and up to 2 years after
the index date and stratified by a 1-month period are presented in Fig. S3. Although there was some variability, mean
costs PPPM were on average higher in TRD than non-TRD
MDD cohorts ($US1762–2863 vs. 839–1757) each month.

4 Discussion

*Significant at the 5% level

d
Suicide-related costs were defined as all costs during a visit with any of the following ICD-9-CM diagnostic codes: E95x, V62.84 and ICD-10-CM diagnostic codes T14.91x, X71.x-X83.x,
T36.x- T65.x with a suffix of ‘2’ indicating ‘intentional self-harm’, T71.x with a suffix of ‘2’ indicating ‘intentional self-harm’, R45.851

Depression-related costs were defined as all costs during a visit with any of the following ICD-9-CM diagnostic codes: 296.2x, 296.3x, 300.4x, 309.0x, 309.1x, 311.xx and ICD-10-CM diagnostic codes F32.x, F33.x, F34.1, or F43.21

c

Psychiatric pharmacy costs include the following classes of agents (generic product identifier prefix): anxiolytics (‘57’), antidepressants (‘58’), antipsychotics/antimanics (‘59’), anticonvulsants
(‘7299’, ‘721’, ‘726’), and other mood stabilizers (e.g., lithium)

b

Table 2  (continued)
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The results of this retrospective matched-cohort analysis
demonstrated that patients with TRD in IDN settings across
the US had a longer duration of antidepressant therapy and
a greater number of unique antidepressant medications than
patients with MDD that were not resistant to treatment and
than patients without MDD. From baseline to follow-up,
TRD patients had higher costs and rates of HRU than did
non-TRD MDD and non-MDD patients. All-cause medical
and pharmacy costs were also higher, on average, among
TRD patients. During the baseline period, TRD patients had
higher rates of HRU, particularly behavioral health-related
HRU than did non-TRD MDD patients and non-MDD
patients. TRD patients also had higher healthcare costs, with
inpatient costs serving as the main driver of this increased
adjusted cost difference.
In this study, healthcare costs were considerably high
and contrary to expectations that IDNs are associated with
lower costs [11, 15, 30]. Instead, the higher HRU and costs
among TRD patients relative to non-TRD MDD or nonMDD patients in this study aligned with previous commercial claims-based studies of patients treated in non-IDN
settings [6, 8, 9, 31, 32]. A recent study, by Amos et al.
[8], evaluated HRU and costs among commercially insured
TRD patients using a similar study design as the present
study, which allows for indirect comparisons. Results of
that analysis demonstrated that the rates of HRU for TRD
patients were higher than rates for patients in the non-TRD
MDD and non-MDD cohorts (2.0 and 4.7 times the rate
of inpatient visits versus the non-TRD MDD and nonMDD cohorts, respectively; all p < 0.001). As in our study,
TRD patients also incurred significantly higher healthcare
costs PPPY than non-TRD MDD patients and non-MDD
patients ($US6709 more than the non-TRD MDD cohort and
$US9917 more than the non-MDD cohort; all p < 0.001).
Interestingly, the adjusted all-cause healthcare cost difference for TRD versus non-TRD MDD patients in this study
were higher than the cost difference reported by Amos et al.
[8] ($US9479 vs. 6709). Given our IDN definition, the
difference in costs may result from linking outpatient and
inpatient institutions, which can increase the costs of both
outpatient and inpatient care, as suggested by previous literature on IDNs [33]. Another potential explanation to account
for this difference could be the continuity of care provided
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Fig. 3  All-cause healthcare costs per patient per year measured from
the index date up to 2 years post-index datea,b. aMultivariable ordinary least squares regression included baseline all-cause healthcare
costs and Quan-CCI; bTotal costs are presented in the black text.
Medical and pharmacy costs are presented in the green and blue texts,

respectively. *Significant at the 5% level. CI confidence interval, ED
emergency department, MDD major depressive disorder, PPPY per
patient per year, Quan-CCI Quan-Charlson comorbidity index, TRD
treatment-resistant depression

by healthcare providers in IDNs resulting in an increased
awareness of patients’ worsening symptoms, which would
require additional care and ultimately contribute to greater
HRU and costs.
To the best of our knowledge, this is the first study to
highlight treatment patterns, HRU, and costs associated
with TRD, non-TRD MDD, and non-MDD patients treated
in US IDNs. As a result, direct comparisons with other
studies are a challenge because of the differences in study
parameters and patient populations evaluated. However, one
study published in 2003, by Liu et al. [34], examined the cost
effectiveness of collaborative care for veterans with MDD
and reported an increase in costs associated with collaborative care. As expected, their explanation for the higher
costs were the greater resources needed to adequately treat
MDD patients. Despite methodological differences between
that study and the present work, it is reasonable to conclude
that the high HRU and costs pertain to the greater needs of
the TRD patient population. The HRU and costs among the
cohorts in this study provide a useful benchmark to help
direct efforts in reducing the health and economic burdens
associated with MDD, particularly TRD. Consequently, this
study fills an important knowledge gap for IDN decision
makers regarding real-world treatment patterns and cost differences for TRD patients, which significantly contributes to
the overall burden of MDD.
Although the results of this study do not support lower
costs among TRD or non-TRD MDD patients treated in

IDNs, it is possible that the true benefit of IDNs among
these patient populations is in the quality of care received.
Given the care coordination among providers across a
continuum of settings, IDNs are particularly relevant for
patients with behavioral health disorders [19, 35]. Several studies have documented improved patient outcomes
within IDNs for patients with depressive disorders [36–39].
For example, one study based on longitudinal data found
that patients treated in highly integrated programs had
greater improvement in self-reported physical health and
mental health recovery assessed by their clinician [40].
Another study that compared outcomes among patients
with depression who received collaborative care and those
who received usual care found that collaborative care was
associated with significant improvement in adherence to
therapy (75 vs. 50%), patient perception of quality of care
(93 vs. 75%), and patient-reported improvement in efficacy
of antidepressant therapy (88 vs. 63%) [36]. The fact that
several studies highlight improved quality of care among
heterogeneous patient populations underscores the value of
IDNs. It is possible that the higher quality of care may result
in reduced costs long term; however, additional studies are
warranted to explore this possibility among TRD, non-TRD
MDD, and non-MDD patients treated across different types
of IDNs versus non-IDN settings.
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4.1 Limitations
This study should be interpreted within the context of certain limitations. First, the treatment failure algorithm used
to identify patients with TRD relied solely on pharmacy
claims; clinical considerations to specifically assess treatment failure, response, and remission could not be incorporated. Furthermore, the algorithm used to identify the
TRD study population may not be representative of all
TRD patients as only patients with an adequate dose and
duration of antidepressant were selected. Second, because
patients with a single IDN visit were included in the analysis, it is possible that some of the patients evaluated did
not experience the care associated with multiple visits to an
IDN. Additionally, once patients are seen in an IDN, they
remain flagged as IDN patients even if they later receive
care in a non-IDN setting. Although this may prevent us
from accurately identifying patients who are truly seen in
an IDN setting, we hypothesized that patients seen in an
IDN typically prefer to continue their care within the same
IDN in which they were initially seen based on available
literature on patient experience in IDNs [33, 41]. Third, PS
matching based on demographic variables was conducted to
minimize the confounding between the TRD and non-TRD
MDD or non-MDD cohorts. However, since imbalances
remained after matching, we further adjusted for baseline
Quan-CCI and all-cause healthcare costs. Although PS
matching and adjustment techniques were used to minimize
the potential confounding, these comparisons may still be
subject to residual confounding from unmeasured confounders. Fourth, to evaluate baseline characteristics and study
outcomes, a minimum of 6 months of continuous enrollment
in a health insurance plan before and after the index date was
imposed on the study population. However, patients who do
not have ≥ 6 months of continuous enrollment before or after
the index date may have differed in the continuity of care
received. This may limit the generalizability of the HRU and
cost burden reported in this study. Lastly, there is currently
no industry standard to define an IDN [15]. In this study,
an IDN was defined as a coordinated hospital inpatient and
outpatient system offering healthcare services in a defined
geographical region. Therefore, the results may not be generalizable to all US IDNs.

5 Conclusions
Patients with TRD who received care in IDNs had higher
HRU and incremental costs than patients with MDD who
were not resistant to treatment and those without MDD.
The HRU and economic burden associated with TRD were
substantial in the US IDN setting and was mainly driven by
non-behavioral health-related HRU and costs.
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